Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
In this article from Cancer Health, Doreen talks about her life after her diagnosis of small lymphocytic lymphoma (SLL), and how it changed her priorities.
In this video, Dr. John N. Allan, M.D., an Assistant Professor of Medicine at Weill Cornell Medicine and a CLL specialist at New York-Presbyterian/Columbia University Irving Medical Center, is interviewed by CLL Society founder and Chief Medical Officer, Dr. Brian Koffman, M.D., a retired family physician and a CLL patient.
In this video, Dr. Matthew Davids, M.D., an Associate Professor of Medicine at Harvard Medical School and the Director of Clinical Research for Lymphoma at Dana-Farber Cancer Institute in Boston, discusses his views on treatment strategies of patients with chronic lymphocytic leukemia (CLL). This video was recorded at the 62nd Annual Meeting of the American Society of Hematology, held virtually in December 2020. Dr. Davids specializes in CLL and serves on the CLL Society’s Medical Advisory Board.
The team at Dana-Farber Cancer Institute is testing whether the combination of duvelisib (Copiktra™) and venetoclax (Venclexta®) will lead to deep remissions that would allow for oral only therapy of one year duration. Learn more about this ongoing Phase I/II clinical trial.
The treatment landscape for those of us with CLL / SLL has changed dramatically in the past decade or less. We see decreasing reliance on chemoimmunotherapies that were the only option in the past. We have seen a move from sequential use of targeted therapies to control our CLL to combinations of drugs that allow patients to attain undetectable MRD.
ASH 2020: Dr. John Allan on Bispecific Antibodies for Chronic Lymphocytic Leukemia (CLL)
ASH 2020: Dr. Ian Flinn on Combination Zanubrutinib and Venetoclax for Treating Chronic Lymphocytic Leukemia (CLL)
ASH 2020: Dr. Tanya Siddiqi provides an Update on the TRANSCEND CLL 004 Trial: Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)
To learn more information about how this revolutionary “living drug” works, the steps involved, insurance coverage, and eligibility, please read this short CAR-T infographic as well as other topics from the CAR-T Working Group.
One click to our most popular content.
